Search
Dbv Technologies SA
DBVTAdd to Watchlist
15.820USD
+0.090+0.57%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
950.90MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Dbv Technologies SA is 7.67, ranking 95 out of 157 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 35.00 and a low of 7.94.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
38.333
Target Price
+139.58%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
Dbv Technologies SA
DBVT
6
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
36
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Dbv Technologies SA's expected revenue for the next quarter?
Dbv Technologies SA's expected revenue is 918.20K.
What is Dbv Technologies SA's price target?
Analysts forecast that Dbv Technologies SA's price target is USD 20.00, with the highest forecast at USD 35.00 and the lowest forecast at USD 7.94.
How have Dbv Technologies SADBVT's recent earnings per share performed?
The market expectation was USD -0.56, while Dbv Technologies SADBVT's earnings per share (EPS) for the previous quarter was USD -1.22. EPS for the next quarter is expected at USD -0.11.
What is the analyst rating for Dbv Technologies SA?
Based on the ratings of Dbv Technologies SA's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.